EP0202222A1 - Produit de recalcification des tissus - Google Patents

Produit de recalcification des tissus

Info

Publication number
EP0202222A1
EP0202222A1 EP19850900341 EP85900341A EP0202222A1 EP 0202222 A1 EP0202222 A1 EP 0202222A1 EP 19850900341 EP19850900341 EP 19850900341 EP 85900341 A EP85900341 A EP 85900341A EP 0202222 A1 EP0202222 A1 EP 0202222A1
Authority
EP
European Patent Office
Prior art keywords
mixture
silica
recited
elemental
potassium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19850900341
Other languages
German (de)
English (en)
Inventor
Stephen D. Sawruk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0202222A1 publication Critical patent/EP0202222A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients

Definitions

  • This invention is concerned with a novel combination of organic nutrients which is highly useful in the re-calcifi ⁇ cation of calcium-depleted tissues and, in particular, which is useful in replacing the so-called cortical boney matrix of the bone that constitutes the middle layer in the structure of the bone.
  • Such calcium depletion is commonly caused by such phenomenon as aging., malnutrition, and injury to the bone per se.
  • the present invention comprises a combination of natur ⁇ ally occurring silica such as vegetal silica which includes the compound silicon dioxide; and commonly occurring potassium such as potassium gluconate, the Combination of which is in approximately equal parts.
  • the combination is employed as a dietary supplement; thereby; the resulting elemental potassium acts to promote absorption of the elemental silicon into the bloodstream.
  • the elemental silicon then, together with carbon derived from normal biological processes (the breakdown of carbohy ⁇ drates) , serves in a catalytic transmutational function in order to bring about the deposition of calcium into the areas
  • Mineral-containing mixtures in accordance with the pre ⁇ sent invention include a physical admixture of herbal silica and elemental potassium (K) .
  • her ⁇ bal silica is derived in the form of vegetal silica from the equisetum species of plant.
  • the chemical formula for the vegetal silica is the same as that for inorganic silicon di ⁇ oxide (Si0 2 ) •
  • elemental potassium in the form of potassium glu- conate. It is to be appreciated that there are other sources from which elemental potassium may be derived, e.g., potassium biocarbonate and other naturally occurring products such as kelp which is rich in elemental potassium. It is contemplated that equal quantities of vegetal sil and potassium gluconate will be mixed and sold as a dietary supplement, this mixture containing neither sugar, starch, artificial coloring nor pre ⁇ servatives.
  • Another ingredient that may be added is an analgesic.
  • the sole function of the elemental potassium is to promote the absorption of the silica into the bloodstream; that is, the only function of the potas ⁇ sium is to act as a carrier of the silica into the bloodstream.
  • the silica Once the silica has entered the bloodstream, it will separate into its components of silicon and oxygen. After this has occurred, the silicon will co-act with free carbon in the bloodstream (this carbon having been derived from normal met ⁇ abolic processes including the breakdown of hydrocarbons) in order to jointly act as a transmutational catalyst to enhance the formation of calcium within the bones and, as noted, to particularly enhance the re-calcification of the comical boney matrix (the middle layer) of the bones.
  • a combination of free silicon and carbon will serve as a cat ⁇ alyst to enable depleted bone tissue to become re-calcified.
  • the chemistry herein involved is essentially identical to that as which occurs in the formation of limestone as well ⁇ in certain organic processes including the formation of calcium within the shells of eggs of aieves (the bird family) .
  • silicon and carbon have been found to perform a useful catalytic function in the enhancement of calcium deposition in bones in the human body.
  • the selection of a 500 mg level for the vegetal silica and potassium gluconate is based upon established safe levels of said ingredients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Un agent de recalcification agit sur des tissus osseux humains. L'agent de recalcification comprend un mélange de silice végétale et de gluconate de potassium.
EP19850900341 1984-11-27 1984-11-27 Produit de recalcification des tissus Withdrawn EP0202222A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1984/001948 WO1986003121A1 (fr) 1984-11-27 1984-11-27 Produit de recalcification des tissus

Publications (1)

Publication Number Publication Date
EP0202222A1 true EP0202222A1 (fr) 1986-11-26

Family

ID=22182344

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19850900341 Withdrawn EP0202222A1 (fr) 1984-11-27 1984-11-27 Produit de recalcification des tissus

Country Status (2)

Country Link
EP (1) EP0202222A1 (fr)
WO (1) WO1986003121A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5035898A (en) * 1987-11-27 1991-07-30 Schering Corporation Potassium/magnesium supplement
DE59808607D1 (de) * 1997-11-18 2003-07-10 Energybalance Ag Ruggell Mineralstoffgemisch mit verbessertem Geschmack

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1513298A (en) * 1923-01-11 1924-10-28 John W Turrentine Therapeutic product and process of preparing same
US4259315A (en) * 1980-06-13 1981-03-31 A. H. Robins Company, Inc. Controlled release potassium dosage form

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8603121A1 *

Also Published As

Publication number Publication date
WO1986003121A1 (fr) 1986-06-05

Similar Documents

Publication Publication Date Title
Greenwood Fluoride intoxication
Heppel The electrolytes of muscle and liver in potassium-depleted rats
WO1994001006A2 (fr) Composition destinee a etre utilisee comme aliment ou comme complement alimentaire
KR870006853A (ko) 굴 엑스 탈색 농축물의 제조방법
EP0202222A1 (fr) Produit de recalcification des tissus
Pillai et al. Role of protozoa in the aerobic purification of sewage
Royle A manual of materia medica and therapeutics
JPH0853358A (ja) 吸収性に優れたカルシウム組成物
Givens Studies in calcium and magnesium metabolism. IV. Experiments on man
RU2220737C1 (ru) Лечебно-профилактическая композиция "остеомакс экстра" для улучшения функционального состояния опорно-двигательного аппарата
US5620709A (en) Calcium containing composition from sea urchin with high oral bioavailability
RU2119756C1 (ru) Гематоген
RU2030178C1 (ru) Адаптогенное средство
Deichmann et al. Pain in jawbones and teeth in ciguatera intoxications
Macbride Experimental Essays on Medical and Philosophical Subjects...
Funamoto et al. Binding of strontium vs calcium to 17β-estradiol-induced proteins in the plasma of the goldfish Carassius auratus
Royle Materia Medica and Therapeutics...
KR20210063539A (ko) 식이 유황을 함유하는 건강보조식품 및 그 제조방법
RU2180176C2 (ru) Способ получения жидкого пищевого продукта для геродиетического питания
BROWN et al. P h ys i o
CN1210690A (zh) 补钙饮食和调味剂
RU2217141C1 (ru) Состав "витализин-1" для профилактики атеросклероза, сердечно-сосудистых заболеваний и поддерживающей терапии вирусных заболеваний
du Vigneaud et al. Effect of the presence of labile methyl groups in the diet on labile methyl neogenesis
KR830002029B1 (ko) 생리적 흡수성이 큰 무기질 원소함유 음료수의 제조방법
JPS62239971A (ja) 保健美容食品の製造法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19861029